Best Treatment For High-Risk Low-Grade Glioma Is Still Radiotherapy
In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
(European Organisation for Research and Treatment of Cancer) In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2013 Category: Global & Universal Source Type: news
Horizon scanning: Phase III Trial investigating cilengitide fails to meet primary endpoint of increasing overall survival in patients with newly diagnosed glioblastoma
Source: PharmaLive
Area: News
According to a report by PharmaLive, a phase III trial investigating cilengitide for newly diagnosed glioblastoma has failed to meet the primary endpoint, of increasing overall survival.
The phase III trial CENTRIC, was a randomised, controlled, multi-centre open-label trial which evaluated the safety and efficacy of cilengitide in combination with temozolomide and radiotherapy in more than 500 patients with newly diagnosed glioblastoma and methylated MGMT gene promoter status. (Source: NeLM - News)
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news
Cilengitide fails to meet primary endpoint in patients with newly diagnosed glioblastoma
Merck Serono, a division of Merck, Darmstadt, Germany, has announced that the Phase III CENTRIC trial of the investigational integrin inhibitor cilengitide did not meet its primary endpoint of significantly increasing overall survival when added to the current standard chemoradiotherapy regimen (temozolomide and radiotherapy). (Source: Pharmacy Europe)
Source: Pharmacy Europe - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
RCT: Tremelimumab does not improve survival in advanced melanoma
Source: JCO
Area: News
The Journal of Clinical Oncology has featured a study evaluating the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab compared with standard-of-care chemotherapy in patients with advanced melanoma.
The phase III trial involved 655 patients with treatment-naive, unresectable stage IIIc or IV melanoma who were randomised to receive tremelimumab (15 mg/kg once every 90 days) or physician's choice of standard-of-care chemotherapy (temozolomide or dacarbazine). Tumour responses were assessed every 90 days (one cycle) in patients treated with tremelimumab, e...
Source: NeLM - News - January 8, 2013 Category: Drugs & Pharmacology Source Type: news
